Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home
Share
Compartir

Report of Expert Consultations on Rapid Molecular Testing to Detect Drug-Resistant Tuberculosis in the United States

Figure 1: Flow Chart of Steps in a molecular drug-resistance testing service

Flow Chart of steps in a molecular drug-resistance testing service, see below for text version

Figure 2: Reflex Testing

Flow chart Figure 2: Reflex Testing, see below for text version

Figure1: Flow Chart of steps in a molecular drug-resistance testing service alternative text version

Program develops and disseminates criteria and protocol for accessing molecular DR testing service
<down arrow>
Clinicians identify samples meeting criteria and receive permission to submit to molecular DR testing lab
<down arrow>
Samples shipped to molecular DR testing laboratory
<down arrow>
Samples received and accessioned by molecular DR testing laboratory
<down arrow>
Perform molecular DR test <side input arrow>IQC, EQA, PT
<2 down arrows>
Rif resistant or RIF susceptible

Rif Resistant (phone and electronic report)
<2 down arrows>
Report result within two business days of receipt of specimen then/or Initiate reflex testing protocol 1st & 2nd line conventional DST AND Additional molecular DR tests
<up arrow into Initiate reflex testing protocol 1st & 2nd line conventional DST AND Additional molecular DR tests>
See Figure 2 for reflex testing

RIF susceptible (electronic report)
<down arrow>
Report result within two business days of receipt of specimen
<down arrow>
Program and health care provider take action based on results
<down arrow>
Discrepant results identified
<down arrow>
Isolates shipped to Referee Lab.  Additional molecular and conventional DST conducted

Figure 2: Reflex Testing alternative text version

Rifampin resistance is detected
<down arrow>
Notify designated individuals by phone – e.g., TB Program, TB Laboratory, Clinician, submitter
<down arrow>
Initiate reflex testing protocol
The TB Program is responsible for paying for conventional drug-susceptibility testing and is responsible for the testing algorithm. Program must ensure clear communication between service providers and facilitate sample referral, tracking, and reporting.
<2 down arrows>
culture or specimen

Culture
<down arrow>
Molecular DR testing Lab, State TB Lab, or submitter
Initiate 1st & 2nd line DST in-house or
Ship isolate to DST lab
Ship portion to CDC
<2 down arrows>
Additional molecular DR tests at contract lab or CDC or Identify discrepant results
<down arrow>
Isolates shipped to Referee Lab for additional genetic (DNA sequencing) and conventional DST

Specimen
<down arrow>
Molecular DR testing Lab, State TB Lab, or submitter
Inoculate liquid media
incubate culture or ship to DST lab
Initiate 1st & 2nd line DST
Ship portion of culture to CDC
<2 down arrows>
Additional molecular DR tests at contract lab or CDC or Identify discrepant results
<down arrow>
Isolates shipped to Referee Lab for additional genetic (DNA sequencing) and conventional DST

 

 
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #